Consensus conference: Implementing treatment recommendations on yttrium-90 immunotherapy in clinical practice – Report of a European workshop-Reference-Cited by-同舟云学术

Consensus conference: Implementing treatment recommendations on yttrium-90 immunotherapy in clinical practice – Report of a European workshop

Published:2008-02 Issue:3 Volume:44 Page:366-373
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Zinzani Pier Luigi,d’Amore Francesco,Bombardieri Emilio,Brammer Caroline,Codina José Gómez,Illidge Tim,Jurczak Wojciech,Linkesch Werner,Morschhauser Franck,Vandenberghe Elisabeth,Van Hoof Achiel

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference45 articles.

1. Natural history of and therapy for the indolent non-Hodgkin’s lymphomas;Horning;Semin Oncol,1993

2. Improved survival of follicular lymphoma patients in the United States;Swenson;J Clin Oncol,2005

3. Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma;Zinzani;J Clin Oncol,2004

4. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group

5. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma;Marcus;Blood,2005

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Reactor-Produced Therapeutic Radionuclides;Radiopharmaceuticals for Therapy;2016

2. Long term efficacy and safety of Fludarabine, Cyclophosphamide and Rituximab regimen followed by 90Y-ibritumomab tiuxetan consolidation for the treatment of relapsed grades 1 and 2 follicular lymphoma;Experimental Hematology & Oncology;2015-06-24

3. Clinical Practice Guidelines and Consensus Statements in Oncology – An Assessment of Their Methodological Quality;PLoS ONE;2014-10-17

4. The status of radioimmunotherapy in CD20+ non-Hodgkin’s lymphoma;Targeted Oncology;2014-05-29

5. Phase I Study of a Modified Regimen of 90Yttrium–Ibritumomab Tiuxetan for Relapsed or Refractory Follicular or Transformed CD20+ Non-Hodgkin Lymphoma;Cancer Biotherapy and Radiopharmaceuticals;2013-06